マクロライド系抗生物質の世界市場レポート 2025年

マクロライド系抗生物質市場規模は、今後数年で急成長が見込まれます。2029年の年間平均成長率（CAGR）は11.5％で、1,020億9,000万米ドルに成長します。予測期間の成長は、呼吸器感染症の発生、併用療法の増加、世界の高齢者人口の増加、認知度の向上と診断、遠隔医療とオンライン薬局サービスの成長などの要因による呼吸器感染症の増加に起因すると考えられます。予測期間における主な動向としては、ドラッグデリバリー・システムや製剤の進歩、新規マクロライド系抗生物質の開発、遠隔医療や遠隔ヘルスケアサービスの進歩、マクロライド系抗生物質の環境に優しい製造プロセスの開発などが挙げられます。

マクロライド系抗生物質市場の成長は、今後数年間における皮膚感染症の有病率の増加によって牽引されると予想されます。皮膚感染症は、有害な微生物が皮膚に侵入して炎症を引き起こし、多くの場合、発赤、腫れ、痛みなどの症状を伴う。皮膚感染症増加の要因としては、不衛生な生活習慣、免疫力の低下、環境汚染物質への暴露、抗生物質耐性、不十分な創傷ケアなどが挙げられます。マクロライド系抗生物質は、黄色ブドウ球菌や化膿レンサ球菌などの細菌によって引き起こされる皮膚感染症の治療、特にペニシリンアレルギーや耐性の場合によく処方されます。例えば、2022年9月の英国健康安全保障局（UKHSA）によると、皮膚・軟部組織感染症に起因するメチシリン耐性黄色ブドウ球菌（MRSA）菌血症例の割合は、2020年4月～2021年3月と2021年4月～2022年3月の間に25.7％から33.7％に増加しました。同様に、メチシリン感受性黄色ブドウ球菌（MSSA）菌血症についても、同期間に27.2%から28.5%に増加しており、皮膚感染症の増加動向がマクロライド系抗生物質市場を牽引しています。

マクロライド系抗生物質市場の主要企業は、アクセシビリティの向上、治療コストの削減、市場プレゼンス拡大のため、ジェネリック製剤の開発にますます注力しています。マクロライド系抗生物質のジェネリック医薬品は、有効成分、用量、強さは先発品と同じであるが、一般的に低価格で販売されています。例えば、米国を拠点とする製薬会社ファントム・ファーマシューティカルズは2022年5月、成人のヘリコバクター・ピロリ（ピロリ菌）感染を治療する目的で設計された2つの新製品「VOQUEZNA TRIPLE PAK」と「VOQUEZNA DUAL PAK」を発売しました。VOQUEZNA TRIPLE PAKにはvonoprazan（カリウム競合型アシッドブロッカー、PCAB）、アモキシシリン、クラリスロマイシンが、VOQUEZNA DUAL PAKにはvonoprazanとアモキシシリンが含まれています。vonoprazanの導入は、米国で30年以上ぶりに承認された新しいクラスの制酸剤であり、重要な進歩を意味します。ジェネリック製剤への移行は、患者にとって治療へのアクセスや購入しやすさを向上させるとともに、マクロライド系抗生物質の市場を拡大させるものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界マクロライド系抗生物質PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のマクロライド系抗生物質市場：成長率分析
• 世界のマクロライド系抗生物質市場の実績：規模と成長, 2019-2024
• 世界のマクロライド系抗生物質市場の予測：規模と成長, 2024-2029, 2034F
• 世界マクロライド系抗生物質総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のマクロライド系抗生物質市場薬物によって、実績と予測, 2019-2024, 2024-2029F, 2034F
• アジスロマイシン
• クラリスロマイシン
• エリスロマイシン
• フィダキソマイシン
• テリスロマイシン
• 世界のマクロライド系抗生物質市場適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 呼吸器感染症
• 皮膚感染症
• 性感染症
• 胃腸感染症
• その他の適応症
• 世界のマクロライド系抗生物質市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界のマクロライド系抗生物質市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• ドラッグストアと薬局
• オンラインプロバイダー
• 世界のマクロライド系抗生物質市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 皮膚科クリニック
• クリニック
• 外来センター
• 調査室
• 世界のマクロライド系抗生物質市場アジスロマイシンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口錠
• 経口懸濁液
• 注射
• 世界のマクロライド系抗生物質市場クラリスロマイシンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 即放錠
• 徐放錠
• 経口懸濁液
• 世界のマクロライド系抗生物質市場エリスロマイシンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• タブレット
• カプセル
• 局所溶液
• 注射
• 世界のマクロライド系抗生物質市場フィダキソマイシンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口錠
• 世界のマクロライド系抗生物質市場テリトロマイシンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口錠

第7章 地域別・国別分析

• 世界のマクロライド系抗生物質市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のマクロライド系抗生物質市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• マクロライド系抗生物質市場：競合情勢
• マクロライド系抗生物質市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck Sharp & Dohme Corp Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi S.A
• Bristol-Myers Squibb Company
• Abbott Laboratories
• Novartis AG
• GlaxoSmithKline plc.
• Eli Lily and Company
• Amgen Inc.
• Teva Pharmaceutical Industries Limited
• Mylan N.V.
• Daiichi Sankyo
• Sun Pharmaceutical Industries Limited
• Cipla Limited
• Lupin Limited
• Zydus Lifesciences Limited
• Alkem Laboratories Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• マクロライド系抗生物質市場2029：新たな機会を提供する国
• マクロライド系抗生物質市場2029：新たな機会を提供するセグメント
• マクロライド系抗生物質市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Macrolide antibiotics are characterized by a macrocyclic lactone ring to which one or more sugars are attached. They exert their antibacterial effect by binding to the 50S ribosomal subunit, thereby inhibiting bacterial protein synthesis. This mechanism makes them effective against a wide range of Gram-positive bacteria and some Gram-negative bacteria.

Azithromycin, clarithromycin, erythromycin, fidaxomicin, and telithromycin are the main types of macrolide antibiotics. Azithromycin, for instance, inhibits bacterial growth by disrupting protein synthesis. It is used to treat respiratory tract infections, skin infections, sexually transmitted infections, gastrointestinal infections, among others. Azithromycin can be administered orally, parenterally, or through other routes. It is distributed through hospital pharmacies, retail drug stores, and online providers, and is utilized by various end users such as hospitals, dermatology clinics, outpatient clinics, ambulatory centers, and research laboratories.

The macrolide antibiotics market research report is one of a series of new reports from The Business Research Company that provides macrolide antibiotics market statistics, including macrolide antibiotics industry global market size, regional shares, competitors with a macrolide antibiotics market share, detailed macrolide antibiotics market segments, market trends and opportunities, and any further data you may need to thrive in the macrolide antibiotics industry. This macrolide antibiotics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The macrolide antibiotics market size has grown rapidly in recent years. It will grow from $59.07 billion in 2024 to $66.02 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to increasing antibiotic resistance, approvals for new formulations, a rise in infectious diseases, and government and healthcare initiatives.

The macrolide antibiotics market size is expected to see rapid growth in the next few years. It will grow to $102.09 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to a rise in respiratory infections due to factors like arise in respiratory infections, rise in combination therapies, an increase in the global geriatric population, increased awareness and diagnostics, and growth in telemedicine and online pharmacy services. Major trends in the forecast period include advancements in drug delivery systems and formulations, the development of novel macrolide antibiotics, advancements in telemedicine and remote healthcare services, and the development of eco-friendly manufacturing processes for macrolide antibiotics.

The growth of the macrolide antibiotics market is expected to be driven by the increasing prevalence of skin infections in the coming years. Skin infections occur when harmful microorganisms invade the skin, causing inflammation and often accompanied by symptoms such as redness, swelling, and pain. Factors contributing to the rise in skin infections include poor hygiene practices, compromised immune systems, exposure to environmental pollutants, antibiotic resistance, and inadequate wound care. Macrolide antibiotics are commonly prescribed to treat skin infections caused by bacteria such as Staphylococcus aureus or Streptococcus pyogenes, especially in cases of penicillin allergy or resistance. For example, according to the UK Health Security Agency (UKHSA) in September 2022, the percentage of Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia cases attributed to skin and soft tissue infections increased from 25.7% to 33.7% between April 2020 to March 2021 and April 2021 to March 2022. Similarly, for Methicillin-Sensitive Staphylococcus aureus (MSSA) bacteremia cases, the percentage rose from 27.2% to 28.5% over the same period, indicating a rising trend in skin infections driving the macrolide antibiotics market.

Major companies in the macrolide antibiotic market are increasingly focusing on developing generic formulations to improve accessibility, reduce treatment costs, and expand their market presence. Generic versions of macrolide antibiotics contain the same active ingredients, dosage, and strength as their branded counterparts but are typically sold at lower prices. For example, in May 2022, Phantom Pharmaceuticals, a US-based pharmaceutical company, launched two new products-VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK-designed to treat Helicobacter pylori (H. pylori) infection in adults. The VOQUEZNA TRIPLE PAK contains vonoprazan (a potassium-competitive acid blocker or PCAB), amoxicillin, and clarithromycin, while the VOQUEZNA DUAL PAK includes vonoprazan and amoxicillin. The introduction of vonoprazan marks a significant advancement, as it represents the first new class of acid suppressants approved in the U.S. in over 30 years. This move towards generic formulations helps improve treatment accessibility and affordability for patients while expanding the market for macrolide antibiotics.

In April 2024, Aztiq, an Iceland-based long-term investment fund, acquired Alvogen Emerging Markets Holdings Limited from PTT Public Company Limited for an undisclosed sum. The acquisition aims to accelerate Adalvo's growth and expansion by leveraging the combined strengths of Aztiq and Innobic (Asia), PTT's wholly-owned Life Science arm. Adalvo, a US-based pharmaceutical company, specializes in providing macrolide antibiotics.

Major companies operating in the macrolide antibiotics market are Pfizer Inc., Roche Holding AG, Merck Sharp & Dohme Corp, AbbVie Inc., Bayer AG, Sanofi S.A, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc., Eli Lily and Company, Amgen Inc., Teva Pharmaceutical Industries Limited, Mylan N.V., Daiichi Sankyo, Sun Pharmaceutical Industries Limited, Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Alkem Laboratories Ltd., Zhejiang Guobang Pharmaceutical Co. Ltd., Fresenius Kabi USA, WOCKHARDT, Crescent Pharma Limited, Wellona Pharma Private Limited

North America was the largest region in the macrolide antibiotics market in 2024. The regions covered in the macrolide antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the macrolide antibiotics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The macrolide antibiotics market consists of sales of oral tablets and capsules such as dirithromycin, josamycin, spiramycin, and roxithromycin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Macrolide Antibiotics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on macrolide antibiotics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for macrolide antibiotics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The macrolide antibiotics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drugs: Azithromycin; Clarithromycin; Erythromycin; Fidaxomicin; Telithromycin
• 2) By Indication: Respiratory Tract Infections; Skin Infections; Sexually Transmitted Infections; Gastrointestinal Infections; Other Indications
• 3) By Route Of Administration: Oral; Parenteral; Other Route Of Administrations
• 4) By Distribution Channel: Hospital Pharmacies; Drug Stores And Retail Pharmacies; Online Providers
• 5) By End User: Hospital; Dermatology Clinic; Clinic; Ambulatory Centre; Research Laboratories
• Subsegments:
• 1) By Azithromycin: Oral Tablets; Oral Suspension; Injection
• 2) By Clarithromycin: Immediate-Release Tablets; Extended-Release Tablets; Oral Suspension
• 3) By Erythromycin: Tablets; Capsules; Topical Solution; Injection
• 4) By Fidaxomicin: Oral Tablets
• 5) By Telithromycin: Oral Tablets
• Companies Mentioned: Pfizer Inc.; Roche Holding AG; Merck Sharp & Dohme Corp; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Macrolide Antibiotics Market Characteristics

3. Macrolide Antibiotics Market Trends And Strategies

4. Macrolide Antibiotics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Macrolide Antibiotics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Macrolide Antibiotics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Macrolide Antibiotics Market Growth Rate Analysis
• 5.4. Global Macrolide Antibiotics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Macrolide Antibiotics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Macrolide Antibiotics Total Addressable Market (TAM)

6. Macrolide Antibiotics Market Segmentation

• 6.1. Global Macrolide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Azithromycin
• Clarithromycin
• Erythromycin
• Fidaxomicin
• Telithromycin
• 6.2. Global Macrolide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Respiratory Tract Infections
• Skin Infections
• Sexually Transmitted Infections
• Gastrointestinal Infections
• Other Indications
• 6.3. Global Macrolide Antibiotics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Route Of Administrations
• 6.4. Global Macrolide Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Drug Stores And Retail Pharmacies
• Online Providers
• 6.5. Global Macrolide Antibiotics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Dermatology Clinic
• Clinic
• Ambulatory Centre
• Research Laboratories
• 6.6. Global Macrolide Antibiotics Market, Sub-Segmentation Of Azithromycin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Tablets
• Oral Suspension
• Injection
• 6.7. Global Macrolide Antibiotics Market, Sub-Segmentation Of Clarithromycin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immediate-Release Tablets
• Extended-Release Tablets
• Oral Suspension
• 6.8. Global Macrolide Antibiotics Market, Sub-Segmentation Of Erythromycin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablets
• Capsules
• Topical Solution
• Injection
• 6.9. Global Macrolide Antibiotics Market, Sub-Segmentation Of Fidaxomicin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Tablets
• 6.10. Global Macrolide Antibiotics Market, Sub-Segmentation Of Telithromycin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Tablets

7. Macrolide Antibiotics Market Regional And Country Analysis

• 7.1. Global Macrolide Antibiotics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Macrolide Antibiotics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Macrolide Antibiotics Market

• 8.1. Asia-Pacific Macrolide Antibiotics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Macrolide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Macrolide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Macrolide Antibiotics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Macrolide Antibiotics Market

• 9.1. China Macrolide Antibiotics Market Overview
• 9.2. China Macrolide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Macrolide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Macrolide Antibiotics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Macrolide Antibiotics Market

• 10.1. India Macrolide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Macrolide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Macrolide Antibiotics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Macrolide Antibiotics Market

• 11.1. Japan Macrolide Antibiotics Market Overview
• 11.2. Japan Macrolide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Macrolide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Macrolide Antibiotics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Macrolide Antibiotics Market

• 12.1. Australia Macrolide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Macrolide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Macrolide Antibiotics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Macrolide Antibiotics Market

• 13.1. Indonesia Macrolide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Macrolide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Macrolide Antibiotics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Macrolide Antibiotics Market

• 14.1. South Korea Macrolide Antibiotics Market Overview
• 14.2. South Korea Macrolide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Macrolide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Macrolide Antibiotics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Macrolide Antibiotics Market

• 15.1. Western Europe Macrolide Antibiotics Market Overview
• 15.2. Western Europe Macrolide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Macrolide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Macrolide Antibiotics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Macrolide Antibiotics Market

• 16.1. UK Macrolide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Macrolide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Macrolide Antibiotics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Macrolide Antibiotics Market

• 17.1. Germany Macrolide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Macrolide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Macrolide Antibiotics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Macrolide Antibiotics Market

• 18.1. France Macrolide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Macrolide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Macrolide Antibiotics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Macrolide Antibiotics Market

• 19.1. Italy Macrolide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Macrolide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Macrolide Antibiotics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Macrolide Antibiotics Market

• 20.1. Spain Macrolide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Macrolide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Macrolide Antibiotics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Macrolide Antibiotics Market

• 21.1. Eastern Europe Macrolide Antibiotics Market Overview
• 21.2. Eastern Europe Macrolide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Macrolide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Macrolide Antibiotics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Macrolide Antibiotics Market

• 22.1. Russia Macrolide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Macrolide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Macrolide Antibiotics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Macrolide Antibiotics Market

• 23.1. North America Macrolide Antibiotics Market Overview
• 23.2. North America Macrolide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Macrolide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Macrolide Antibiotics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Macrolide Antibiotics Market

• 24.1. USA Macrolide Antibiotics Market Overview
• 24.2. USA Macrolide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Macrolide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Macrolide Antibiotics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Macrolide Antibiotics Market

• 25.1. Canada Macrolide Antibiotics Market Overview
• 25.2. Canada Macrolide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Macrolide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Macrolide Antibiotics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Macrolide Antibiotics Market

• 26.1. South America Macrolide Antibiotics Market Overview
• 26.2. South America Macrolide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Macrolide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Macrolide Antibiotics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Macrolide Antibiotics Market

• 27.1. Brazil Macrolide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Macrolide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Macrolide Antibiotics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Macrolide Antibiotics Market

• 28.1. Middle East Macrolide Antibiotics Market Overview
• 28.2. Middle East Macrolide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Macrolide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Macrolide Antibiotics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Macrolide Antibiotics Market

• 29.1. Africa Macrolide Antibiotics Market Overview
• 29.2. Africa Macrolide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Macrolide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Macrolide Antibiotics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Macrolide Antibiotics Market Competitive Landscape And Company Profiles

• 30.1. Macrolide Antibiotics Market Competitive Landscape
• 30.2. Macrolide Antibiotics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck Sharp & Dohme Corp Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Macrolide Antibiotics Market Other Major And Innovative Companies

• 31.1. Sanofi S.A
• 31.2. Bristol-Myers Squibb Company
• 31.3. Abbott Laboratories
• 31.4. Novartis AG
• 31.5. GlaxoSmithKline plc.
• 31.6. Eli Lily and Company
• 31.7. Amgen Inc.
• 31.8. Teva Pharmaceutical Industries Limited
• 31.9. Mylan N.V.
• 31.10. Daiichi Sankyo
• 31.11. Sun Pharmaceutical Industries Limited
• 31.12. Cipla Limited
• 31.13. Lupin Limited
• 31.14. Zydus Lifesciences Limited
• 31.15. Alkem Laboratories Ltd.

32. Global Macrolide Antibiotics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Macrolide Antibiotics Market

34. Recent Developments In The Macrolide Antibiotics Market

35. Macrolide Antibiotics Market High Potential Countries, Segments and Strategies

• 35.1 Macrolide Antibiotics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Macrolide Antibiotics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Macrolide Antibiotics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer